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Oxidative stress is characterized by an imbalance between pro-oxidant and antioxidant 
species, leading to macromolecular damage, and disruption of redox signaling and cellular 
control. It is a hallmark of various diseases including metabolic syndrome, chronic fatigue 
syndrome, neurodegenerative, cardiovascular, inflammatory, as well as age-related diseases. 
Several mitochondrial defects have been considered to contribute to the development of 
oxidative stress, and known as the major mediators of the aging process and subsequent age-
associated diseases. Thus mitochondrial targeted antioxidants should prevent or slow down 
these processes and prolong longevity. This is the reason while antioxidant treatments are 
extensively studied, and newer and newer compounds with such an effect appear. 
Astaxanthin, a xanthophyl carotenoid is the most abundant carotenoid in marine organisms, 
and is one of the most powerful natural compounds with remarkable antioxidant activity. Here 
we summarize its antioxidant targets, effects, and benefits in diseases and with aging. 
 
INTRODUCTION 
The extended human life span over the past decades is causing world’s population to aging. 
Accordingly, the prevalence of chronic diseases, cognitive decline and disability increases in 
the aged population [1]. The first theory to explain the cellular and molecular background of 
aging was the Free Radical Theory of Aging (FRTA), proposed in the 1950’s [2] and has 
become one of the most studied theories. The basic idea of this theory is that reactive oxygen 
species and free radicals generated during physiological metabolism and arising from 
reactions to exogenous factors, initiate degradation of biomolecules and the progressive 
accumulation of these cellular damages ultimately results in aging and age-related diseases. 
Because of increasing inconsistent evidence, it is now accepted that this theory in its original 
form or its variants cannot alone explain the aging process [3, 4]. Nevertheless, FRTA cannot 
be rejected in its entirety, since an impressive amount of data indicates that reactive oxygen 
species (ROS)-mediated aging phenotypes and age-related disorders (aside from spontaneous 
errors in signaling pathways and reactions of metabolites, e.g. reactive aldehydes and sugars) 
[5-10] exist.  
In normal metabolic cells, the production of reactive oxygen and nitrogen species 
(ROS/RNS) from several sources and their removal by antioxidant systems, including 
endogenous or exogenous antioxidant molecules, are very precisely balanced. Mitochondria 
play a major role in supporting the redox balance, so maintaining structural and functional 
integrity of these organelles is essential for normal cellular function. At physiological 
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concentrations ROS/RNS are crucial in signaling processes. These ROS/RNS are produced at 
very low levels and the damage caused is almost instantly repaired. The antioxidant enzymes 
within the cells like catalase, superoxide dismutase (SOD), lactoperoxidases and glutathione 
peroxidase inhibit the production of such free radicals and thus present a protecting effect on 
cells maintaining the balance.  
Oxidative stress is defined as an imbalance between pro-oxidants and antioxidants, 
resulting in macromolecular damage and disruption of redox signaling and cellular control 
[11]. Pro-oxidants are factors that help to generate ROS, which in turn destroy cellular 
macromolecules, i.e. induce protein oxidation, lipid peroxidation, and DNA damage [12]. 
mtDNA due to its proximity to the site of ROS production was thought to be intrinsically 
vulnerable [13]. By contrast, antioxidants reduce oxidative stress, since they act to counter or 
reduce the effects of ROS [14]. 
Mitochondrial defects have been proposed to contribute to the development of 
oxidative stress-related diseases [15, 16]. Impaired mitochondrial function has been involved 
in various human diseases, particularly, it is considered as the main mediator of the aging 
process and subsequent age-related diseases [17, 18]. If the reactions of free radicals and other 
oxygen species contribute to accumulation of molecular damages giving rise to aging and age-
related diseases, antioxidants should prevent or slow down these processes and prolong 
longevity. Based on this assumption a huge amount of studies were established and aimed at 
estimating the effect of level of endogenous antioxidants and/or of administration of 
exogenous antioxidants on aging and age-related processes and diseases. 
The antioxidant’s positive effects are verified by the experimental biological 
observations which have found that long-term administration of Vitamin C decreased 
isoprostanes levels in rats [19]. Vitamin C was shown to decrease the α-tocopheroxyl level in 
membranes or low-density lipoprotein (LDL) and inhibits α-tocopheroxyl radical mediated 
propagation [20]. Protective effect of Vitamin E against oxidative damage was also 
demonstrated. It is explained by its direct action on a variety of oxygen radicals. The 
mechanism of action of antioxidants seem to be widespread: they might directly neutralize 
free radicals, they quench iron subsequently decrease ROS production, they decrease the 
concentration of peroxide and restore oxidized membranes [21]. Antioxidants are considered 
as a chemical to be able to induce antioxidant gene expression, to prevent LDL cholesterol 




Carotenoids have gained special interest during the last decades, due to their strong 
antioxidant, repairing, anti-proliferative, anti-inﬂammatory and potential antiaging effects. 
They can be used to prevent oxidative stress-related diseases and chronic inﬂammation. 
Astaxanthin is one of the most powerful carotenoid on the market. In this review special focus 
is oriented towards these compounds. 
 
THE MODE OF ACTION OF RETINOIDS 
Vitamin A (retinol) and its derivatives with or without biological activity, collectively referred 
to as retinoids, are crucial for normal development and homeostasis of vertebrates. The only 
source of retinoids is through diet (milk, liver, eggs), because these compounds cannot be 
synthesized de novo [23]. Retinoids have long been appreciated as essential factors for 
controlling the differentiation program of certain epithelial cells and for their benefic effects 
on vision, growth, reproduction and resistance to infection [24]. The predominant natural 
retinoid in circulation is retinol that is transported at high concentrations (micro molar levels) 
via the serum bound to retinol-binding protein (RBP) and from there it can be taken up by any 
cell for storage or potential conversion into retinoic acid (RA). Once inside the cell retinol is 
converted into retinal via a reversible reaction catalyzed by short-chain 
dehydrogenase/reductases (SDRs). In this reaction the first step is the conversion to 
retinaldehyde with the concomitant generation of NADH and lastly the formation of retinoic 
acid by cytosolic aldehyde dehydrogenases (Figure 1). Retinoic acid can bind to and activate 
nuclear hormone receptors [retinoic acid receptor (RAR) and retinoid X receptor (RXR). 
Three different RXR isotypes (RXR α, β, γ) have been reported so far [25, 26]. RXRγ has 
limited tissue expression including high levels in the brain, anterior pituitary, and skeletal 
muscle [27]. 
Retinoic acid, the active metabolite of vitamin A, has notable effects on lipid and 
energy metabolism by modulating the phosphorylation state of AMPK and Akt [28] and the 
rate of glucose uptake in L6 myotubes [29]. Treatment of mice with all-trans retinoic acid 
(atRA) was described to reduce body weight and adiposity independently of changes in food 
intake, improved insulin sensitivity and glucose tolerance in lean and obese mice [30, 31] and 
was found to promote skeletal muscle fatty acid oxidation [32] and irisin production in 
skeletal muscles [32]. 
SDRs are ubiquitary expressed and constitute a large protein family involved in the 
reduction of a variety of substrates. SRP-35 (Sarcoplasmic Reticulum Protein of 35 kDa) was 
identified using a proteomic approach by Treves et al. [33] and it belongs to the DHRS7C 
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subfamily [34]. In muscle cells, using retinol as its substrate SRP-35 was proposed as a target 
to affect glucose metabolism in human patients with metabolic disorders [35]. The 
biochemical characterization of SRP-35 firmly support that it is a membrane-bound protein 
with its catalytic site facing the cytoplasm; as a consequence both its products (retinaldehyde) 
and NAD(P)H are released into the myoplasm. The generation of NADH in the myoplasm 
may possess functional signaling relevance; lactate dehydrogenase requires NADH as 
reducing power to generate lactate from pyruvate and NADH is available in the mitochondria 
where it is used to generate ATP. Nevertheless, cytosolic NADH has been shown to regulate 
the activity of the RyRs, especially in the heart [36, 37]. 
 
ASTAXANTHIN, A SPECIAL CAROTENOID 
Carotenoids, the precursors of vitamin A, are natural pigments supplied with regular highly 
conjugated π-bond systems, providing the natural yellow, orange, or red colors of many 
vegetable and fruits [38]. Since the structural elucidation of β-carotene by the two scientists 
Kuhn and Karrer in 1930, more than 750 naturally occurring carotenoids have been reported 
to date [39]. Based on their structure, carotenoids can be compiled into two main groups: (i) 
the carotenes, also called carotenoid hydrocarbons, which only contain carbon and hydrogen; 
and (ii) the xanthophyls or oxygenated carotenoids that may contain different functional 
groups (epoxy, methoxy, hydroxy, carbonyl, and carboxyl acid groups) [40, 41].  
Besides the most notable carotenoid, β-carotene, another carotenoid has been receiving 
great attention lately: astaxanthin, a marine xanthophyl carotenoid first isolated from a lobster 
by Kuhn and Sorensen [42]. Astaxanthin is extensively produced by algal species such as 
Haematococcus pluvialis (where it accumulates up to 3.8% on the dry weight basis), 
Chlorella zofingiensis, Chlorococcum, and also by the yeast Phaffia rhodozyma [43, 44]. 
Astaxanthin confers the rich pink color observed in various aquatic species including the 
salmonids and crustaceans, and even some nonaquatic species such as the flamingo. Sea 
creatures cannot produce astaxanthin themselves and must obtain it from their diets, which 
include zooplankton and krill. Krill oil contains appreciable content of astaxanthin at 0.1 to 
1.5 mg/mL depending on processing methods [45]. Krill oil is a superior source of EPA 
(eicosapentaenoic acid) and DHA (docosahexaenoic acid) which are both long chain omega-3 
fatty acids because the polyunsaturated fats are packaged as phospholipids, which ultimately 
can be used instantly by our body. 
Astaxanthin is a fat-soluble nutrient (it incorporates into cell membranes) with 
increased absorption when consumed with omega-3 rich seed oil; however, it cannot be 
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converted to vitamin A and therefore can’t support retinol-specific processes such as vision. 
With its unique molecular structure [46], astaxanthin stretches through the bilayer membrane, 
providing resilient protection against oxidative stress. It can scavenge and quench ROS and 
free radicals (superoxide anion, hydrogen peroxide, singlet oxygen, etc.) in both the inner and 
outer layers of the cellular membrane [46] unlike most antioxidants, which work either in the 
inner (e.g., vitamin E and β carotene) or the outer side of the membrane (e.g., vitamin C). 
Astaxanthin derived from the microalgae H. pluvialis has been approved as a color additive 
agent in salmon feeds and as a dietary supplement for human consumption for more than 20 
years in dosages up to 12 mg per day and up to 24 mg per day for no more than 30 days in 
Europe, Japan, and the USA[47].  
Recent human studies elaborate on the safety perspectives of natural astaxanthin and 
so far no documented negative effects have been found over its 20 years of consumption as a 
dietary [48]. Clinical studies have found that natural astaxanthin supplementation improved 
blood flow in humans [49], and enhanced blood rheology by increasing flexibility of 
erythrocyte membranes [50]. 
Astaxanthin emerged in the spotlight because of its potential pharmacological effects, 
including anticancer [44, 51, 52], antidiabetic [53, 54], anti-inflammatory [55], immune-
stimulating effects [44, 52], and antioxidant activities [55-59] as well as neuro-, 
cardiovascular, ocular, and skin-protective effects [60-64]. Studies found that astaxanthin 
reduces the oxidative stress caused by hyperglycemia in pancreatic β-cells and improves 
glucose and serum insulin levels in diabetes [65]. Furthermore, it has been suggested that 
astaxanthin is a potential therapeutic agent against atherosclerotic cardiovascular disease [66]. 
In an elegant work, Barros et al. showed that “astaxanthin can directly cross the blood-brain 
barrier to reach different mammalian brain regions” [64, 67, 68]. Here we summarize the 
effects of astaxanthin on metabolism, insulin resistance and type-2 diabetes mellitus; 
furthermore, its advantages on muscle performance, recovery and atrophy, and the effects in 
central nervous system and skin will also be discussed. 
 
THE METABOLIC EFFECTS OF ASTAXANTHIN 
Insulin-mediated glucose uptake 
Skeletal muscle accounts for 30-40 % of body mass. As the major metabolic tissue of the 
body, it plays an important role in the whole-body metabolism and homeostasis. In the 
postprandial state, skeletal muscle tissue is responsible for over 80 % of insulin-induced 
glucose uptake. The molecular mechanisms of insulin-mediated glucose transport are 
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intensively studied. GLUT4 (glucose transporter type 4) is a glucose transporter responsible 
for glucose uptake into adipocytes and muscle tissue. The GLUT4 vesicles are mainly found 
perinuclearly at a basal state which are translocated to the plasma membrane by insulin-
regulated vesicular traffic leading to glucose transport into the cells and a simultaneous 
decrease of blood glucose. Importantly, in case of insulin resistance and type-2 diabetes 
mellitus the amount of GLUT4 is decreased [69] and its translocation is impaired [70]. The 
insulin receptor signaling involves the insulin receptor substrate (IRS)-1 mediated activation 
of PI3K (phosphatidylinositol-3-kinase), resulting in Akt2 activation, inhibition of the Akt2 
substrate AS160 (Akt substrate 160; a GTPase activating protein for Rabs), and consequently 
the activation of Rab8a and Rab14 GTPases in muscle cells [71]. The PI3K can also activate 
the Rho-family GTPase Rac1 that involved in the remodeling of cortical actin network by 
regulating the Arp2/3 complex and cofilin influencing GLUT4 translocation [72]. The joint 
activation of the PI3K-mediated Akt2/AS160 and Rac1 signaling pathways is necessary for 
the translocation of GLUT4 (Figure 2).  
 
Oxidative stress and insulin resistance 
Insulin resistance is a definition for insufficient response of tissues to the effect of insulin, 
resulting decreased insulin-mediated glucose uptake into the skeletal muscle, increased 
hepatic glucose production in the liver and impaired suppression of lipolysis in adipose tissue. 
The development of insulin resistance is an intensively studied, complex and not fully known 
process. Numerous papers have reported that the mitochondrial dysfunction is linked to 
insulin resistance and type-2 diabetes mellitus [73-75]; however, it remains unclear whether 
perturbations in mitochondrial functional capacity are causes, consequences, or key 
contributors to insulin resistance [74, 76]. Mitochondria are the major sources of reactive 
oxygen species. Insulin resistance is characterized by inefficient mitochondrial coupling, low 
level of ATP, and the formation of excess amount of ROS despite the normal to high oxygen 
consumption [73, 75]. Mitochondrial dysfunction was first described in glucose intolerance in 
1975 [77]. Several studies suggested that the loss in mitochondrial content and/or function, 
and consequently the decreased mitochondrial oxidative capacity leads to insufficient lipid 
oxidation, accumulation of lipid excess resulting in the development of insulin resistance [74]. 
The accumulation of ROS can activate various kinases such as PKC (protein kinases C)s, IKK 
β (inhibitor κB kinase-β), JNK (c-Jun N-terminal kinase) and p38 MAPK (mitogen-activated 
protein kinase), which induce the phosphorylation of serine residues in IRS-1 leading to the 
inhibition of its activity and directing it to proteasomal degradation [74, 78-81]. JNK1 has a 
8 
 
crucial role in the development of insulin resistance by inhibiting IRS activity via 
phosphorylation of Ser307 residue preventing its interaction with the insulin receptor [82, 83]. 
Furthermore, oxidative stress inhibits the retromer function in a casein kinase-2 (CK2)-
dependent manner leading to the sorting of GLUT4 vesicles to lysosomes for degradation [84] 
(Figure 2 ).  
 
Astaxanthin treatment, insulin sensitivity, and muscle metabolism 
Astaxanthin accumulated in skeletal muscle, and was shown to reduce hyperglycemia and 
ameliorate insulin secretion and sensitivity by improvement of glucose metabolism and β-cell 
dysfunction by GLUT4 regulation. Astaxanthin administration increased the translocation of 
GLUT4 transporter and also insulin-dependent glucose uptake in line with increased 
phosphorylation of IRS-1 tyrosin and Akt and a decrease in JNK and IRS-1 Ser307 
phosphorylation in L6 muscle cells [85]. Inflammatory cytokines (e.g. TNF, tumor necrosis 
factor ) and fatty acids are released from adipose tissue and serve as the major contributors 
to induce insulin resistance [85, 86]. Palmitate generate ceramide which triggers 
mitochondrial oxidative stress and insulin resistance [87]; and the role of TNF in the 
generation of insulin resistance was also shown [86]. Importantly, astaxanthin treatment 
restored TNF- and palmitate-induced insulin resistance, and decreased ROS generation of 
L6 muscle cells [85]. 
Astaxanthin treatment (8 mg/day, 8 weeks) was effective in patients with type-2 
diabetes mellitus: reduced visceral fat mass, serum triglyceride, very-low-density lipoprotein 
cholesterol concentration and decreased systolic blood pressure. Furthermore, astaxanthin 
significantly reduced the fructosamine and plasma glucose concentration [54]. In a metabolic 
syndrome model SHR/NDmcr-cp (cp/cp) rats where spontaneous hypertension, obesity, 
hyperinsulinemia, and mild hyperlipidemia evolved, the astaxanthin treatment (22 weeks) 
ameliorated features of metabolic syndrome: improved insulin resistance, decreased fasting 
blood glucose, homeostasis of insulin resistance (HOMA-IR), triglyceride, and fatty acid 
levels, induced a significant reduction of arterial blood pressure and the size of fat cells in 
white adipose tissue [88]. Astaxanthin ameliorated high-fat, cholesterol and cholate diet-
induced glucose intolerance, reversed hepatic inflammation and fibrosis in C57BL/6J mice 
[89]. Moreover, astaxanthin administration in a type-2 diabetic db/db (leptin receptor 
mutated) mice improved intraperitoneal glucose tolerance test, and protected pancreatic β-
cells against glucose toxicity by reducing blood glucose concentration and hyperglycemia-
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induced oxidative stress [65]. Insulin resistance can also be detected in another animal model 
(High Fat and High Fructose Diet-fed mice), where the astaxanthin treatment improved their 
insulin sensitivity parameters [53]: lowered insulin and glucose levels in the plasma, 
ameliorated insulin signaling, and enhanced Akt phosphorylation and GLUT4 translocation is 
skeletal muscle [53].  
The number and function of mitochondria influences fatty acid utilization of the 
skeletal muscle. The peroxisome proliferator-activated receptor-γ coactivator -1a (PGC-1) is 
a key transcriptional co-activator playing a role in the biogenesis of mitochondria in the 
muscle. PGC-1 was significantly elevated in skeletal muscle samples following astaxanthin 
intake, and cytochrome C levels were also increased in mice [90]. Moreover, the levels of 
plasma fatty acids were decreased after exercise in the astaxanthin-fed mice [90], and the fat 
utilization of skeletal muscle was improved during exercise in a treadmill running model by 
activation of carnitine palmitoyltransferase I [91]. Interestingly, PGC-1 increases the level 
of GLUT4 and has multiple roles in the pathogenesis of type-2 diabetes mellitus [92], but the 
effects of astaxanthin on PGC-1/GLUT4 pathway has not been studied. It has also been 
demonstrated that peroxisome proliferator-activated receptor (PPAR), which has a major role 
in the carbohydrate metabolism, is a novel target for astaxanthin. The antioxidant molecule 
can bind dose-dependently to PPARγ and act as an antagonist or an agonist depending on the 
cell context [93]. 
 
Protective effect of astaxanthin on diabetes mellitus complications 
Diabetes mellitus increases ROS production and also decreases antioxidant defense capacity. 
Reactive radicals are produced in several ways, one source is the activated macrophages and 
neutrophils. Release of large amounts of ROS leads to oxidative stress of all cell components 
and induces chronic inflammatory responses [81, 94]. It has also been suggested that 
carotenoids are capable to protect the different tissues from the long-term consequences of 
diabetes including nephropathy, infectious diseases, and abnormalities in the neuronal system 
and eye. Several reports try to examine and discuss the mechanisms behind the biological 
effects of carotenoids for the prevention of the complications of diabetes mellitus. 
Astaxanthin supplementation markedly reduced the level of inflammation-related 
proteins COX-2 (cyclooxygenase-2), iNOS (inducible nitric oxide synthase), MCP-1 
(monocyte chemoattractant protein 1), NF-β (nuclear factor beta) in the liver and the ROS-
induced lipid peroxidation in Streptozotocin-induced diabetic rats [95]. In human mesangial 
10 
 
cells astaxanthin prevented the high glucose exposure induced elevated ROS production in the 
mitochondria, so it can have a protective effect against diabetic neuropathy [96]. In human 
neutrophil cells astaxanthin prevented the high glucose-induced ROS/RNS production and 
improved the phagocytic capacity of the cells [97]. The redox balance in the lymphocytes was 
ameliorated by astaxanthin application via lowering the activities of catalase, restoring ratio 
between glutathione peroxidase and glutathione reductase activities and lowering the scores of 
lipid oxidation in alloxan-induced diabetic rat model [98]. Inflammation-related neuronal 
apoptosis leads to learning and memory deficits. Astaxanthin decreased the activity of 
apoptosis-related molecules (TNF, IL-1, IL-6) and caspase 3 and 9 in the cortex and 
hippocampus of diabetic rats improving cognitive deficits [99]. High glucose concentration-
induced superoxide, nitric oxid and peroxynitrite generation was also reduced by astaxanthin 
treatment in proximal tubular epithelial cell, which inhibited the nuclear translocation of NF-
κB p65 subunit [100]. Oxidative stress is the major cause of renal fibrosis during the 
progression of diabetic nephropathy. In diabetic (db/db) mice astaxanthin administration 
improved the development and acceleration of diabetic nephropathy [101]; it improved 
experimental diabetes-induced renal oxidative stress, and prevented renal fibrosis by 
upregulating connexin43 and activating the antioxidant Nrf2(NF-E2-related factor 2 )-
ARE(antioxidant responsive element) pathway in glomerular mesangial cells [102]. In 
streptozotocin-induced diabetic rats 12 weeks of astaxanthin treatment ameliorated 
morphological changes in the kidney via decreasing the protein expression of fibronectin and 
collagen IV, and through the activation of Nrf2-ARE signaling [103]. Therapeutic effect of 
astaxanthin and other carotenoids regarding long-term complications of diabetes mellitus has 
been demonstrated in a review of Roohbakhsh et al [104]. 
 
EFFECTS OF ASTAXANTHIN ON MUSCLE PERFORMANCE, RECOVERY, AND 
ATROPHY 
Effects of antioxidants and their targets in skeletal muscle work 
During skeletal muscle work ROS are generated from either mitochondrial or non-
mitochondrial sources. These include NADPH, xanthine oxidases, phospholipase A2, and 
nitric oxide that originates from NO synthase. During moderate exercise oxidative balance is 
kept within physiological limits to minimize the effects of oxidative damage [105]. It contains 
a complicated antioxidant defense system: antioxidant enzymes like glutathione peroxidases, 
superoxide dismutase (SOD), thioredoxins, peroxiredoxins, and catalase. They are capable to 
reduce ROS, while endogenous antioxidant substrates such as glutathione can scavenge 
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ROS/RNS [105]. Physical exercise per se has antioxidant effects by enhancing these 
endogenous antioxidant defense [106], and in pathological conditions, like diabetes or cancer, 
this endogenous antioxidant effect is probably the most efficient health-promoting 
mechanism. Despite this, antioxidant treatment is very popular and widely used in medical 
treatment and also among individuals doing recreational or professional sports to enhance 
activity. These treatments can modifies skeletal muscle signaling like force production, 
glucose uptake, insulin sensitivity, ion pump functions, and mitochondrial biogenesis [105]. 
However, the frequently supplemented antioxidants are usually vitamin C and E which 
generalized, non-target scavengers of all ROS. This leads to the fact that in some cases these 
antioxidant supplementation does not decrease, or may even increase, the incidence of human 
diseases [107] explaining the urgent need of new, more specifically working antioxidant 
compounds. 
Mitochondria has essential role in skeletal muscle contraction. This is the place of 
ATP synthesis, modulates redox status, controls pH, and contributes in physiological calcium 
ho-homeostasis. Since without ATP and calcium muscle fibers do not contract, any alteration 
on mitochondrial status could lead to myopathy or muscle related disease like diabetes. It was 
shown that chronic exercise increased mitochondrial size and density, and its cardiolipin 
content in type 2 diabetes [108]. In Barth Syndrome, which is an X-linked recessive disorder 
manifesting in muscle weakness and cardiomyopathy, dysfunction of tafazzin (a 
mitochondrial acyltransferase) reduces cardiolipin content, and alters mitochondrial function. 
Treatment with mito-Tempo (a mitochondria-specific antioxidant) in cardiac myocytes 
lacking tafazzin normalized its level, decreased mitochondrial ROS production and increased 
cellular ATP content [109]. Unfortunately, not all the mitochondria targeted treatment have 
beneficial effects. Recent study shows in Barth Syndrome again, that a targeted 
overexpression of catalase in mitochondria did not prevent the development of myopathy in 
mice [110]. Next to the pathological conditions, aging also decreases mitochondrial functions. 
In a special animal model of aging, mtDNA mutator mice (they accumulate errors in their 
mitochondrial DNA and present subsequent changes in the respiratory chain composition) 
were treated with the antioxidant SkQ1 (10-(6’-plastoquinonyl)decyltri-phenylphosphonium 
cation) and the phosphorylation capacity of mitochondria in skeletal muscle was improved 
[111]. This positive effect of SkQ1 was partly because the treatment restored the cardiolipin 
amount in the mtDNA mutator mice to wild-type level. 
 
Effects of astaxanthin during physical exercise and muscle injury 
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During heavy exercise training and competition elevation of reactive oxygen and nitrogen 
species evolve causing damage in lipid, protein and nucleic acid molecules. That is why 
special nutritional strategy, like supplementation with antioxidant compounds is now essential 
for active individuals and athletes. Based upon mice exercise experiments, supplementation 
with astaxanthin can effectively improve side effects of exercise metabolism, the individual´s 
performance and recovery.  
Four weeks of astaxanthin treatment in mice prolonged the running to exhaustion. 
During exercise astaxanthin administration facilitated lipid metabolism instead of glucose 
utilization, which improved the endurance and reduced adipose tissue [91]. The same group 
showed the effect of astaxanthin on ROS-targeted proteins involved in skeletal muscle 
metabolism during exercise. They found that the oxidative stress induced modification of lipid 
peroxidase carnitine palmitoyltransferase I (CPT I) was reduced with the application of 
antioxidant astaxanthin [112]. Liu and coworkers [90] also suggested that astaxanthin intake 
increases PGC-1α level in skeletal muscle leading to the acceleration of lipid utilization by the 
activation of mitochondrial aerobic metabolism during exercise. In oxidative-type soleus 
muscle 45 days astaxanthin supplementation resulted mitochondrial-targeted action, as the 
treatment increased glutathione content in the mitochondria during exercise, limited oxidative 
stress and delayed exhaustion in Wistar rats [113]. 
Unlike in exercising mice model, where astaxanthin supplementation enhanced mainly 
the utilization of fat and depleted muscle glycogen stores during endurance exercise [114], 4 
weeks of treatment did not influence significantly carbohydrate and fat oxidation rate in 
exercising humans [115]. In this study Res et. al. also reported, that there is no significant 
effect of astaxanthin supplementation on performance during endurance training not even on 
longer training time periods or in a higher dose (20 mg/day, 4 weeks) in young, trained 
individuals [115]. Moreover, high carotene-containing diet also proved to be effective to 
moderate some of the negative outcomes of sarcopenia on low physical performance by 
reducing DNA damage in aged humans [116]. It has been proved, that astaxanthin containing 
diet modified the expression level of PGC-1α, thereby induced the mitochondrial biogenesis 
in vivo [90]. It was shown also that the prolonged supplementation hasn’t modified the lipid 
oxidation in order to spare glycogen stores during training, as it already proved in animal 
studies, which can be due to the increased fitness levels of the inspected subjects [91]. Krill 
oil treatment also activated the mTORC1 signaling pathway as it was shown in C2C12 
myoblasts, however, in young, untrained, healthy individuals 3g of krill oil (0.5 g astaxanthin 
content) administration during 8 weeks didn’t elevate significantly the muscle force in 
13 
 
resistance exercise [117]. In elder subjects (between 65-85 years) astaxanthin containing (12 
mg) diet with additional antioxidative properties (10 mg tocotrienol, 6 mg zinc) significantly 
improved the performance in endurance training, additionally enhanced the force and muscle 
mass compared to the control group with placebo and training alone [118]. However, authors 
did not provide information about which signaling pathways were involved and there was also 
a lack of data about the chronic effects of the astaxanthin treatment. 
A fresh study showed that astaxanthin treatment helps to preserve mitochondrial 
integrity and function in heat-induced skeletal muscle injury examined in cultured C2C12 
cells and isolated rat skeletal muscle fibers. The supplementation prevented mitochondrial 
fragmentation and depolarization, reduced apoptotic cell death, increased PGC-1α and 
mitochondrial transcription factor A expression following heat stress [119]. Human 
investigations have also been carried out to show the effect of astaxanthin application on 
exercise induced muscle injury. Eccentric loading was applied for 3 weeks in resistance 
trained men and different markers of muscle injury (muscle soreness, creatine kinase level 
and muscle performance) were tested. According the results the antioxidant supplementation 
did not favorably affect the aforementioned markers [120]. In another study cardiac troponin 
release was examined after endurance-type exercise in cyclists. In this experiment, 
astaxanthin treatment had no effect on antioxidant capacity (uric acid, malondialdehyde) and 
inflammation (high-sensitivity C-reactive protein) markers and did not change creatine kinase 
release induced by exercise [121]. However, positive effect of antioxidant astaxanthin was 
suggested in untrained healthy men, where the supplementation significantly increased 
carbohydrate oxidation, oxygen consumption during exercise and decreased plasma insulin 
level. These results indicate that astaxanthin reach foods can positively affect aerobic 
metabolism of carbohydrate and fat during rest and exercise [122].  
However, several studies using a variety of animal model of myocardial ischemia and 
reperfusion demonstrated efficiency of astaxanthin supplementation by reducing markers of 
oxidative stress and inflammation [123], one has to consider several aspects with regard the 
use of antioxidant nutritional supplementation for attenuating muscle injury. These 
supplements seem to attenuate certain sign of muscle injury during exercise, however it is not 
clear, what is the optimal dose and treatment period and whether the effectiveness is specific 
to non-resistance trained individuals [124]. It is also urgent to find the best markers of skeletal 
muscle injury and more suitable analytical methods so that more reliable conclusion can be 
generated regarding the effect of antioxidant agents like astaxanthin in exercise-induced 
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muscle damage. All the questioned aspects of astaxanthin supplementation on exercise 
performance and recovery has been collected and discussed in a recent review [125]. 
 
Muscle atrophy is ameliorated by astaxanthin treatment  
Skeletal muscle atrophy can occur in case of physiological and several pathological 
conditions such as immobilization, aging, chronic diseases (e.g. heart failure, renal failure), or 
cancer. A correlation between oxidative stress and muscle mass has already been observed, 
the increased production of reactive oxygen species has important roles in disuse muscle 
atrophy by increasing protease activation [126, 127], and the activation of oxidative stress 
pathways in atrophying muscles has been suggested to cause apoptosis. Oxidative stress 
participates in the activation of lysosomal proteases (e.g. cathepsin L), calcium-activated 
proteases (calpain), and also the ubiquitin-proteasome pathway during disuse muscle atrophy 
leading to the activation of proteolysis [126-128]. The effects of antioxidants in disuse 
muscular atrophy have been investigated [129], and the antioxidant astaxanthin come to the 
front as an effective molecule to prevent inactivity-induced muscle atrophy. Astaxanthin 
supplementation prior and/or during hind limb unloading prevented muscle atrophy in 
different animal models. Dietary astaxanthin intake for 14 days before and during hind limb 
immobilization attenuated muscle atrophy in rats, and interfere with the increased expression 
of CuZn-SOD (CuZn-superoxide dismutase), cathepsin L, calpain, and ubiquitin caused by 
immobilization [130]. In another rat model, the dietary astaxanthin supplementation for 2 
weeks prior to unloading and during 7-day long immobilization attenuated soleus muscle 
atrophy and suppressed myonuclear apoptosis measured by the number of TUNEL-positive 
nuclei [131]. The capillary number is related to the loading and activity of skeletal muscle 
[132], the unloading results in capillary regression. Administration of astaxanthin decreased 
the ROS production, decreased the level of SOD-1, and increased the expression of VEGF 
(vascular endothelial growth factor) in the soleus of hind limb unloaded rats [133, 134]; 
furthermore, the 7-day long astaxanthin administration reduced the capillary regression during 
unloading [133], while the 2-week long treatment maintained the capillary network near to 
control levels [134]. Interestingly, the 2-week astaxanthin diet had little effect on soleus 
muscle mass during unloading; other muscles were not examined in this study [134]. Further 
study showed, that the combinatory treatment with dietary astaxanthin supplementation and 
heat stress prevented disuse muscle atrophy in the soleus muscle, and this protective effect 
may be partially due to the higher number of satellite cells (stem cells of the skeletal muscle) 
[135]. Increased ROS production within immobilization-induced skeletal muscle mediates 
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TGF-β1-induced fibrosis via promoting the differentiation of fibroblasts and increasing 
collagen synthesis, where astaxanthin application attenuated skeletal muscle fibrosis [136]. 
Based on a recent paper by Liu at al., astaxanthin formulation in combination with a 
functional training programme increased tibialis anterior muscle size determined from 
magnetic resonance imaging in the elderly [137]. 
 
EFFECTS OF ASTAXANTHIN IN THE CENTRAL NERVOUS SYSTEM AND THE 
SKIN 
Oxidative stress is thought to be involved in the pathogenesis and progression of age-related 
cognitive impairments [138] as well. The high lipid content and metabolic rate make the 
neuronal system particularly vulnerable to oxidative stress. Mitochondrial damage and 
dysfunction due to oxidative stress are reflected in age-related neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson Disease, Huntington’s disease, and amyotrophic 
lateral sclerosis [139]. In addition to metabolic failure, the membrane of the damaged 
mitochondria is impaired, their membrane potentials are lost and they become permeable 
resulting in the release of cytochrome c. These processes lead to the activation of caspases 
that induce apoptosis of neuronal cells. 
Dietary supplementation with antioxidant vitamins has shown preventive action 
against oxidative stress and protected or even reversed the age-related changes in antioxidant 
activity in the central nervous system [140]. In a recent review, Vina and colleagues [141] 
demonstrated that the systemic oxidative stress and the cognitive function in Alzheimer’s 
disease patients are inversely proportional. The administration of antioxidants, such as 
vitamin C or E, has been shown to be effective in reducing the symptoms of oxidative 
stress and cognitive loss [142]. Astaxanthin has recently gained a lot of interest, because 
among its variety of health promoting effects mainly through the modulation of parameters 
related to oxidative stress but also to inﬂammation, it is able to penetrate the blood-brain 
barrier accumulating in the brain, and have evidenced positive eﬀects on neurodegeneration as 
well. The neuroprotective effect of astaxanthin was also published using in vitro and in vivo 
models. The 1-methyl-4-phenylpyridinium (MPP+) toxin was examined which induces 
neuronal cytotoxicity. The oxidative stress evoked by this neurotoxin opens the mitochondrial 
permeability transition pore and subsequently trigger the release of cytochrome c. Astaxanthin 
increases the activity of SOD and catalase, leading to the inhibition of MPP+-induced ROS 
generation [143]. Astaxanthin seems to restore brain derived neurotrophic factor (BDNF) 
levels in both the brains and hippocampus in rats, thereby slowing brain aging [144]. 
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Astaxanthin’s anti-neurotoxic effect was also demonstrated in an in vivo mouse model of 
Parkinson’s disease [145]. A recent review summarizes further information on the potential 
neuroprotective role of astaxanthin [146]. 
Age-related changes of skin are thought to be driven by two basic mechanisms: 
biological aging and exposure to ultra-violet rays (photo aging). Photo aging leads to the 
degradation of components of the extracellular matrix (collagen, elastin), resulting in 
wrinkles, pigmentation, deterioration of the skin texture [147]. UV light initiate production of 
ROS in the skin. Oxidation of C8 guanine base by ROS, 8-hydroxy-2deoxyguanosine (8-
OHdG) is produced, which is a marker of DNA damage [148]. In keratinocytes and 
fibroblasts, ROS activate cytokine receptors and growth factors, that will induce the mitogen-
activated protein kinase (MAP kinase), and subsequently activate transcription factors of 
activator protein-1 (AP-1) [149]. AP-1 potentiates the expression of the matrix degrading 
enzymes, the matrix metalloproteinases (MMPs), which impair collagen in the skin [147]. 
Continuous carotenoid administration demonstrated protection against UV light [150], and in 
particular astaxanthin supplementation had positive impact on aging skin status, the skin 
elasticity was restored, the wrinkle formation was attenuated, and epidermal barrier integrity 
was preserved [151-154]. A comprehensive review of Davinelli et al. summarizes the role of 
astaxanthin in skin physiology [155]. 
 
CONCLUSIONS 
To summarize, the antioxidant astaxanthin has attracted increasing attention as an effective 
molecule to prevent oxidative stress-mediated and age-related diseases. Astaxanthin has been 
reported to lower plasma glucose and insulin levels, and to improve whole body insulin 
sensitivity and insulin-stimulated glucose uptake. Based on the reviewed studies it can act as 
an insulin sensitizer. Astaxanthin also improve disuse muscle atrophy, and it has a 
neuroprotective role and can prevent the photoaging of the skin. Several papers showed that 
the excess amount of ROS involved in the development and progression of chronic diseases, 
including the pathogenesis of insulin resistance and type-2 diabetes. Pinpointing the further 
details of the antioxidant astaxanthin effect can yield translational benefits for people with 
metabolic disease. However, results of studies on the supplementation of model organisms 
with antioxidants, vitamins, and other antioxidants are divergent, many studies show no effect 
or even negative life-prolonging effect. Despite these contradictory conclusions, the beneficial 
effects of antioxidants are undoubted in pathological cases (e.g. antioxidant deficiency), 
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additional studies are needed to demonstrate a positive correlation between antioxidant 
administration and longevity/or slowing aging for healthy people.  
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Figure 2. Astaxanthin improves insulin sensitivity and glucose uptake. Schematic 
representation of the insulin-mediated signaling pathway resulting in the translocation of 
GLUT4 glucose transporter and glucose uptake. The oxidative stress can lead to insulin 
resistance by activating various kinases such as JNK, which catalyse the phosphorylation of 
serine residues in IRS-1 inhibiting its activity and preventing its interaction with the insulin 
receptor. Furthermore, oxidative stress switches the GLUT4 sorting to the degradation of 
GLUT4 vesicles. The dietary astaxanthin administration improves insulin sensitivity, IRS-1 
activation, Akt phosphorylation, and GLUT4 translocation is skeletal muscle leading to 
increased insulin sensitivity and a decrease in blood glucose level. 
 
